Shares of Achaogen Inc. (NASDAQ:AKAO) fell 4.4% during trading on Friday . The company traded as low as $3.65 and last traded at $3.73, with a volume of 78,044 shares changing hands. The stock had previously closed at $3.90.

A number of brokerages have recently commented on AKAO. Zacks Investment Research lowered Achaogen from a “buy” rating to a “hold” rating in a report on Thursday. Needham & Company LLC restated a “hold” rating on shares of Achaogen in a report on Tuesday. Finally, Wedbush upgraded Achaogen from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $7.00 to $10.00 in a report on Tuesday, June 14th.

The company’s market cap is $98.71 million. The stock’s 50 day moving average price is $3.81 and its 200-day moving average price is $3.58.

Achaogen (NASDAQ:AKAO) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.20. The company earned $9.14 million during the quarter, compared to analyst estimates of $5.58 million. The firm’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.05) EPS. On average, analysts expect that Achaogen Inc. will post ($2.52) EPS for the current year.

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.